Condition: Colorectal Cancer · Sponsor: Averto Medical, Inc.
The purpose of this clinical investigation is to evaluate the safety and feasibility of the ColoSeal ICD System in a prospective, multicenter, single-arm study. The ColoSeal ICD System is intended to be used to protect a damaged segment of colon such as a surgical anastomosis, anastomosis leak, or perforation from contact with fecal flow for up to 14 days. The device will be evaluated in adult patients with rectal and rectosigmoid cancer undergoing a resection with a colorectal anastomosis.
This description comes directly from the study's public registry record.
Grace Carlson, MD · 1-415-518-7043 · grace.carlson@avertomed.com
Kenton Fong, MD · 1-650-799-6298 · kenton.fong@avertomed.com
Always discuss trial participation with your own doctor first.
| National Center of Oncology after V.A. Fanarjian | Yerevan, Armenia | Recruiting |
| Israeli-Georgian Medical Research Clinic Healthycore | Tbilisi, Georgia | Completed |
| National Cancer Institute | Tashkent, Uzbekistan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06402188